Published on 04/12/2025
Building a virus safety control strategy for end to end continuous bioprocessing
As the biopharmaceutical industry shifts toward continuous bioprocessing and intensified upstream processes, regulatory expectations for virus safety have become increasingly stringent. These expectations form the foundation for establishing a robust virus safety control strategy that accounts for potential viral contaminants throughout the production process. This article provides a thorough overview of the relevant regulations, guidelines, and agency expectations related to virus safety in continuous bioprocessing.
Context
Viral safety is a paramount concern in the production of biological products, particularly those derived from human or animal sources. Continuous bioprocessing has emerged as a solution to improve efficiency and productivity, as it allows for the uninterrupted flow of materials through the production system. However, the transition to continuous processing introduces complex challenges related to virus contamination risk. Professionals involved in regulatory affairs must possess a deep understanding of the regulations governing viral safety to ensure compliance and safeguard public health.
Legal/Regulatory Basis
The regulatory framework for viral safety in the U.S., EU, and UK is built upon various guidelines and regulations, which outline expectations at every stage of the product
U.S. Regulations
In the United States, the FDA’s Guidance for Industry on the Virus Safety of Human Cells, Tissues, and Cellular and Tissue-Based Products emphasizes the need for appropriate viral safety measures in biological products. Furthermore, 21 CFR Part 211 and 21 CFR Part 610 provide general and specific requirements for biological products, including methods for virus removal and inactivation.
EU Regulations
In the European Union, the Guideline on the Assessment of the Viral Safety of Medicinal Products for Human Use conveys EU expectations for assessing the viral safety of biopharmaceuticals. The revised Standards on Good Manufacturing Practice (GMP) also includes considerations for virus safety as it relates to cellular and gene therapy medicinal products.
UK Regulations
The UK’s regulatory framework mirrors that of the EU, with guidance documents such as the MHRA’s Guidance on Viral Safety providing detailed instructions on compliance with regulatory expectations.
Documentation
Thorough documentation is critical for demonstrating compliance with regulatory expectations concerning viral safety. The documentation should reflect the rationale for the implemented safety measures and the adequacy of viral clearance strategies.
Key Documentation Components
- Viral Clearance Studies: Document the methodologies used for viral clearance (both removal and inactivation) in bioprocessing steps.
- Risk Assessments: Conduct thorough assessments to identify potential viral contamination risks associated with raw materials, processes, and facilities.
- Validation Reports: Validate the performance of processes in regard to viral safety, and maintain records of all validation activities.
- Batch Records: Keep detailed batch records regarding virus safety measures employed during production.
Review/Approval Flow
Understanding the flow of the review and approval process for submissions related to viral safety is essential for regulatory professionals. The following outlines the structured process for addressing viral safety in continuous bioprocessing.
Initial Submission
When submitting a product for regulatory approval, it is imperative to include all relevant information regarding viral safety in the dossier. This includes a comprehensive overview of the virus safety control strategy, viral clearance studies, and risk assessments.
Agency Review
The regulatory agency (FDA, EMA, or MHRA) will review the submitted documentation to ensure compliance with the respective guidelines. Key areas of focus during the review include:
- Assessment of the adequacy of viral clearance studies.
- Evaluation of the identified risks and the effectiveness of the mitigation strategies.
- Verification that the proposed manufacturing methods align with current regulatory expectations.
Approval and Post-Approval Requirements
Post-approval, companies must adhere to ongoing reporting requirements, which may include updates on viral safety data derived from manufacturing experiences or unexpected outbreaks.
Common Deficiencies
Regulatory agencies often identify recurring deficiencies in submissions relating to viral safety. Understanding these common pitfalls can improve the robustness of submittals and enhance overall compliance.
Typical Deficiencies
- Inadequate Viral Clearance Justifications: Failure to provide sufficient justification for the selected viral clearance methods may lead to questions from regulatory agencies.
- Incomplete Risk Assessments: Submitting incomplete risk assessments fails to address potential viral risks associated with starting materials and production processes.
- Lack of Validation Data: Regulatory submissions that lack detailed information on the validation of viral clearance methods may be rejected.
- Insufficient Batch Records: Inconsistent or incomplete batch records can raise concerns during inspections and may lead to regulatory action.
RA-Specific Decision Points
Regulatory affairs professionals must navigate critical decision points throughout the lifecycle of a product, especially with respect to viral safety in continuous bioprocessing.
When to File as Variation vs. New Application
Determining whether a change necessitates a new application or can be classified as a variation is critical. Key considerations include:
- If the changes involve significant alterations to viral safety measures, a new application may be warranted.
- Minor modifications that do not compromise viral safety could be filed as variations.
How to Justify Bridging Data
In continuous bioprocessing, the provision of bridging data becomes vital when the processes evolve. Justifying the need for bridging data should include:
- Clear rationale linking changes to potential viral safety impacts.
- Detailed comparisons between prior and new data to demonstrate ongoing compliance with viral safety standards.
Practical Tips for Documentation and Agency Queries
To promote a successful dialogue with regulatory agencies, consider the following practical tips when addressing documentation and agency queries regarding viral safety:
Best Practices for Documentation
- Maintain comprehensive and consistent records throughout the bioprocessing stages to aid in demonstrating compliance.
- Ensure all documentation is easily accessible for regulatory review and audits.
- Develop a clear template for documenting viral safety protocols and findings, facilitating a standardized approach.
Responding to Agency Queries
When addressing questions from regulatory agencies, it is crucial to remain as precise as possible:
- Directly respond to each query, providing data or rationale to support the discussion.
- Prepare to supply additional data or clarifications as requested, focusing on transparency and comprehensive support.
- Engage with regulatory agencies proactively to clarify expectations and develop a rapport that facilitates better communication.
Conclusion
Building a virus safety control strategy in continuous bioprocessing requires a comprehensive understanding of the regulatory landscape and active engagement with relevant guidelines. By focusing on adequate documentation, understanding the review process, recognizing common deficiencies, and honing the skills needed to navigate RA-specific decision points, professionals can establish robust virus safety measures. This ultimately leads to the successful development and approval of safe biopharmaceuticals that meet stringent regulatory expectations.